Not sure if you guys just decided to go off track or if youre confused, but this is a small molecule, not an anti-sense drug. You are talking about a different drug all together
Well if you read my post you will see that I am not impressed with 21% remission when Celgenes other drug is over 70% effective for Crohns patients and a UC trial is also planned so we were trying to determine if it will be as successful because it release before the large intestine.70% remission rate? Havent heard that before. Ill have to look into it. But this drug had a 58% response rate which is huge; better than remicade and Entyvio if memory servesGood point! Thanks for mentioning that I missed it.
I was very high and Morgensen GED-0301 let me see if I can find the details.
Well from the link above it looks like I rounded up to 70% figure from 67% but the lack of side effects is the deal clincher for me.
- Impressive efficacy
. As we saw in October, the higher GED-301 doses (40mg and
160mg QD) showed stat-sig improvements in remission rates of 55.0% and 65.1%,
respectively. Further, after 12 weeks of treatment, the 40mg and 160mg groups
showed stat-sig improvements in remission rates of 63% and 67%,
We note that CELG has indicated that P3 trials will include a 52-week treat-through
design so will provide longer-term efficacy data.
- Safety also impresses.
Most AEs were mild and reported in 64% of the placebo
group and 65% of patients receiving GED-301. Nine SAEs reported, but no
significant difference between placebo and GED-301 groups.
Post Edited (aguywithuc) : 10/29/2015 9:16:03 AM (GMT-6)